



(12) **United States Patent**  
**Gerber et al.**

(10) **Patent No.:** **US 9,921,176 B2**  
(45) **Date of Patent:** **Mar. 20, 2018**

(54) **SYSTEMS AND METHODS FOR MULTIPLE ANALYTE ANALYSIS**

(71) Applicant: **Roche Diagnostics Operations, Inc.**,  
Indianapolis, IN (US)

(72) Inventors: **Martin T. Gerber**, Carmel, IN (US);  
**Eric Diebold**, Fishers, IN (US)

(73) Assignee: **Roche Diabetes Care, Inc.**,  
Indianapolis, IN (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 282 days.

(21) Appl. No.: **14/625,997**

(22) Filed: **Feb. 19, 2015**

(65) **Prior Publication Data**

US 2015/0300974 A1 Oct. 22, 2015

**Related U.S. Application Data**

(60) Continuation of application No. 14/549,659, filed on Nov. 21, 2014, which is a division of application No. (Continued)

(51) **Int. Cl.**  
**G01N 27/30** (2006.01)  
**G01N 27/327** (2006.01)

(Continued)

(52) **U.S. Cl.**  
CPC ..... **G01N 27/307** (2013.01); **A61B 5/0002** (2013.01); **A61B 5/1486** (2013.01); (Continued)

(58) **Field of Classification Search**  
CPC ..... G01N 27/48; G01N 27/26; G01N 27/327–27/3274; G01N 33/492; (Continued)

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,397,956 A 8/1983 Maggio  
5,071,769 A 12/1991 Kundu et al.  
(Continued)

**FOREIGN PATENT DOCUMENTS**

CN 201438187 U 4/2010  
EP 279069 7/1994  
(Continued)

**OTHER PUBLICATIONS**

T.M. Wallace “Recent advances in monitoring and management of diabetic ketoacidosis” QJM, vol. 87, No. 12, Dec. 2004, p. 773-780.\*

(Continued)

*Primary Examiner* — J. Christopher Ball

(57) **ABSTRACT**

Systems and methods for multiple analyte analysis are provided. In one embodiment, a method includes determining concentrations of first and second analytes in a sample. The first and second analytes may be, for example, glucose and hydroxybutyrate. In this form, an indication related to the measured concentration of hydroxybutyrate is provided in response to determining that the concentration of hydroxybutyrate is above a predetermined value. In a further aspect of this form, a quantitative indication representative of the measured glucose concentration is automatically provided regardless of the value of the measured glucose concentration. In another embodiment, a system includes a meter configured to interact with a test element to assess first and second analytes in a sample. Further embodiments, forms, objects, features, advantages, aspects, and benefits shall become apparent from the description and drawings.

**10 Claims, 12 Drawing Sheets**

